Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
92 participants
INTERVENTIONAL
2004-07-31
2017-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Skeletal Muscle Lipid and Insulin Resistance: Effects of Physical Activity and Weight Loss
NCT00766298
Mitochondrial Impairment in Muscle Insulin Resistance
NCT00222924
The Effects of Altering Physical Activity on Cardiometabolic Health
NCT01879059
Mechanisms of Skeletal Muscle Insulin Resistance in Older Adults
NCT02971098
Basic Research Study to Examine the Relation Between Muscle Insulin Resistance and Lipid Production in the Liver.
NCT02196051
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1. To determine whether aerobic exercise improves both skeletal muscle fat distribution and insulin sensitivity of older men and women. We will test two hypotheses.
i. Physical exercise in older adults will decrease the amount of fat interspersed within muscle, specifically the fat between muscle groups (intermuscular adipose tissue) as well as decrease specific lipid metabolites within muscle cells, compared to controls.
ii. Exercise-induced improvements in insulin sensitivity of older men and women will be related to the changes in muscle fat content independent of changes in total body fat or visceral abdominal adipose tissue.
2. To determine whether increased capacity for oxidative fatty acid metabolism within muscle results in improved insulin sensitivity in older adults. We will test two hypotheses.
i. Exercise training will increase the capacity of muscle to oxidize fatty acids assessed both in vitro and in vivo.
ii. Improved capacity for oxidative fatty acid metabolism will predict improvements in insulin sensitivity.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Exercise Group
Exercise Group
Sixteen week intervention where subjects will be progressed to four days per week for 45 minutes per session, 180 minutes minimum per week, of moderate intensity supervised exercise.
Health Education Group
Health Education Group
Sixteen week intervention. This group will not receive specific exercise education or prescription but will be asked to participate in biweekly health education sessions
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Exercise Group
Sixteen week intervention where subjects will be progressed to four days per week for 45 minutes per session, 180 minutes minimum per week, of moderate intensity supervised exercise.
Health Education Group
Sixteen week intervention. This group will not receive specific exercise education or prescription but will be asked to participate in biweekly health education sessions
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* No weight gain/loss of \>10 lbs in 6 months
* Sedentary (No more than 1 continuous exercise/week) or Highly trained (\>5 exercise sessions/week for a duration of one year or more)
* Non-Smoker
* BMI 18-38.0
* Resting blood pressure less than 150mmHg systolic/95 mmHg diastolic
* Normal glucose tolerance: Fasting glucose \< 100 mg/dl or 2 hour glucose from OGTT \< 140 mg/dl or impaired glucose tolerance (fasting glucose \> 100 mg/dl \< 126 mg/dl or 2 hour glucose from OGTT \> 140 mg/dl but less than 200 mg/dl
* Note from PCP/Cardiologist for exercise clearance if positive stress test symptoms were observed from GXT
Exclusion Criteria
* Peripheral Vascular Disease
* Hepatic, renal, muscular/neuromuscular, or active hematologic/oncologic disease
* Clinically diminished pulse
* Presence of bruits in lower extremities
* Previous history of pulmonary emboli
* Peripheral Neuropathy
* Currently not engaged in a regular program and have a V)2 max pre-training value \> 55 ml/kg-fat free mass-min., indicative of moderate fitness OR currently engaged in regular program and having a V)2 max value \< 55 ml/kg-fat free mass-min.
* Anemia (Hematocrit \< 34%)
* Any contraindications to moderate exercise
* Inability and/or willingness to comply with the protocol as written
* Active alcohol or substance abuse (Past 5 years)
* Total cholesterol \> 300 mg/dL
* Triglyceride \> 350 mg/dL
* ALT \> 80, AST \> 80, Alk Phos \> 240
* Proteinuria (defined as \> 1+ on routine dipstick) hypothyroidism (sTSH\>8)
* Therapeutic Doses of Nicotinic Acid
* Type 2 Diabetes: Fasting Glucose \> 126 mg/dl or 2 hour glucose \> 200 mg/dl
* Oral Glucocorticoids
* Females currently on hormone replacement therapy (HRT) less than 6 months
* Claustrophobia
* Previous difficulty with lidocaine or other local anesthetic
* Stress test symptoms:
* Positive ECG (\>2mm ST segment depression) without PCP cardiologist permission to participate
* Signs or symptoms of cardiovascular decomposition (hypotensive response to exercise
* Onset of angina or angina like symptoms, shortness of breath, change in heart rhythm, signs of poor perfusion (light-headedness), tightness
* Hypotension
60 Years
75 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute on Aging (NIA)
NIH
University of Pittsburgh
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Erin E. Kershaw, M.D.
Associate Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bret H. Goodpaster, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Pittsburgh
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Pittsburgh
Pittsburgh, Pennsylvania, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
0405764
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.